Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine.
Shanghai Key Laboratory of Psychotic Disorders.
Curr Opin Psychiatry. 2021 Jul 1;34(4):369-375. doi: 10.1097/YCO.0000000000000708.
The current article reviews the impact of the biggest health crisis for many decades, coronavirus disease 2019 (COVID-19), on opioid treatment programs and the strategies adopted for maintaining opioid treatment programs during the pandemic.
The difficulty of access to opioid treatment services and the mental health problems accompanying opioid use disorders are the two main challenges to maintaining accessible and effective opioid treatment. Many countries and institutions issued guidance and recommendations to address these challenges. General coping strategies, loosening of policies, telemedicine, and depot buprenorphine are four main strategies to cope with the challenges posed by the pandemic.
There were considerable obstacles to maintaining opioid intervention programs during the COVID-19 pandemic. Strategies addressing the obstacles are identified. Research in this area needs to be strengthened.
本文综述了数十年来最大的健康危机——2019 年冠状病毒病（COVID-19）对阿片类药物治疗方案的影响，以及在大流行期间为维持阿片类药物治疗方案而采取的策略。
获得阿片类药物治疗服务的困难以及伴随阿片类药物使用障碍的心理健康问题是维持可及和有效的阿片类药物治疗的两个主要挑战。许多国家和机构发布了指导意见和建议，以应对这些挑战。一般应对策略、放宽政策、远程医疗和丁丙诺啡储库是应对大流行带来的挑战的四大主要策略。
在 COVID-19 大流行期间，维持阿片类药物干预方案存在相当大的障碍。确定了应对这些障碍的策略。需要加强该领域的研究。
